Short Term Trading Weekend Lounge: 11-13 Oct, page-26

STTCOMP BNO FA Long

MC = $68 Million.
SOI = 544 Million shares.
Share Price = .125c
Cash = $13.98 Million 30/6/19.

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co.

• Cash receipts for the quarter ending 30 June 2019 included receipts from customers totalling $1.92m (31 March 2019: $1.94m).
• Positive FDA feedback at the Type C meeting to discuss BNC210 for the treatment of PTSD
• A request for Fast Track designation for BNC210 has been submitted to the FDA

New pharmacokinetic data from the single ascending doses of BNC210, along with data reported earlier this year demonstrating that the solid dose formulation can overcome the “food effect”, show that the solid dose formulation of BNC210 can reach blood levels required to achieve exposures predicted to give clinically meaningful and statistically significant changes from placebo on Total CAPS-5 scores.
The plasma concentrations and exposures measured in fasted healthy volunteers also increased in a dose proportional manner, demonstrating improved dose linearity with the solid dose formulation compared to the liquid suspension.BNC210 was well tolerated at the exposure levels reached in the healthy volunteers in this study.
Bionomics recently attended a supportive Type C meeting with the FDA to discuss the further development of BNC210 using the solid dose formulation for the treatment of PTSD and subsequently submitted a request for Fast Track designation for BNC210.
The results of this pharmacokinetic clinical trial show that the new solid dose formulation achieves the targeted blood levels to support further development of BNC210 for the treatment of PTSD.